Fortress Biotech, Inc.
NASDAQTotal Valuation
Fortress Biotech, Inc. carries a market capitalization of 131.46M, placing it among publicly traded companies globally. Its enterprise value stands at 568.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 131.46M |
| Enterprise Value | 568.24M |
Share Statistics
Fortress Biotech, Inc. currently has 33.31M shares outstanding.
| Shares Outstanding | 33.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 4.08 |
| P/TBV Ratio | 4.83 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 8.30 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 4.28 |
Financial Position
Fortress Biotech, Inc. maintains a current ratio of 3.96, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.87, indicating elevated leverage, while an interest coverage ratio of -3.46 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.96 |
| Quick Ratio | 3.76 |
| Debt / Equity | 25.87 |
| Debt / EBITDA | -2.15 |
| Interest Coverage | -3.46 |
Financial Efficiency
Fortress Biotech, Inc. posts a return on equity of 99.36 and a return on invested capital of -15.27.
| Return on Equity (ROE) | 99.36 |
| Return on Assets (ROA) | 46.92 |
| Return on Invested Capital (ROIC) | -15.27 |
| Return on Capital Employed (ROCE) | 48.83 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.24 |
Taxes
Over the trailing twelve months, Fortress Biotech, Inc. has paid 4.66M in income taxes, reflecting an effective tax rate of 3.20.
| Income Tax | 4.66M |
| Effective Tax Rate | 3.20 |
Stock Price Statistics
Fortress Biotech, Inc.'s stock has gained approximately 144.85044% over the past 52 weeks. The 50-day moving average sits at 17.94, while the 200-day moving average is 16.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | 144.85044% |
| 50-Day Moving Average | 17.94 |
| 200-Day Moving Average | 16.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -24.75M, while operating income came in at -29.34M.
| Revenue | 68.47M |
| Gross Profit | 44.91M |
| Operating Income | -29.34M |
| Pretax Income | 145.86M |
| Net Income | 111.82M |
| EBITDA | -24.75M |
| EBIT | -29.34M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Fortress Biotech, Inc. holds 196.58M in cash and equivalents against 53.32M in total debt, resulting in a net debt position of -156.97M. Total book value stands at 164.14M, with working capital of 183.49M providing operational flexibility.
| Cash & Cash Equivalents | 196.58M |
| Total Debt | 53.32M |
| Net Debt | -156.97M |
| Equity (Book Value) | 164.14M |
| Book Value Per Share | 4.93 |
| Working Capital | 183.49M |
Cash Flow
Fortress Biotech, Inc. produced 125.92M in operating cash flow over the past twelve months.
| Operating Cash Flow | 125.92M |
| Capital Expenditures | N/A |
| Free Cash Flow | 125.92M |
| FCF Per Share | N/A |
Margins
Fortress Biotech, Inc. operates with a gross margin of 65.59, reflecting its pricing power and cost economics. The operating margin of -42.86 and net profit margin of 163.32 provide insight into operational efficiency.
| Gross Margin | 65.59 |
| Operating Margin | -42.86 |
| Pretax Margin | 213.03 |
| Profit Margin | 163.32 |
| EBITDA Margin | -36.15 |
Dividends & Yields
The company's payout ratio of -4.92 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | -4.92 |
| Shareholder Yield | 0.97 |
| FCF Yield | N/A |
Scores
Fortress Biotech, Inc. posts an Altman Z-Score of 1.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.29 |